AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Celcuity Secures Extended Patent for Breast Cancer Drug, Average Analyst Target Price at $29.00 with 112.77% Upside
ByAinvest
Tuesday, Jul 15, 2025 7:23 am ET1min read
Celcuity has secured a new U.S. patent for its breast cancer drug gedatolisib, ensuring market exclusivity through 2042. The company anticipates clinical data readouts from its Phase III trials, including top-line data for the PIK3CA wild-type patient cohort in Q3 2025. With a strong cash position of $205.7 million, Celcuity is well-equipped to advance its drug development.
Minneapolis, July 2, 2025 — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on developing targeted therapies for oncology, has secured a new U.S. patent for its lead drug candidate, gedatolisib. The patent, U.S. Patent No. 12,350,276, covers the clinical dosing regimen for gedatolisib in ER+/HER2- breast cancer patients, extending Celcuity's market exclusivity in the United States until 2042 [1].The patent issuance is a significant milestone for Celcuity, which has been actively expanding its intellectual property portfolio. The company's patent portfolio now includes 13 granted patents related to gedatolisib in the U.S. and 290 patents internationally [1]. Brian Sullivan, CEO and Co-Founder of Celcuity, emphasized the importance of this patent in strengthening the company's intellectual property portfolio and optimizing the development of gedatolisib.
Celcuity is currently conducting several clinical trials to evaluate the efficacy of gedatolisib. Topline data for the PIK3CA wild-type cohort of the VIKTORIA-1 clinical trial is expected in the third quarter of 2025, while data for the PIK3CA mutant cohort is anticipated in the fourth quarter of 2025 [1]. These clinical trials are crucial for assessing the drug's potential in treating ER+/HER2- advanced breast cancer.
With a strong cash position of $205.7 million, Celcuity is well-positioned to advance its drug development efforts. The company's robust patent portfolio and upcoming clinical data readouts are likely to attract investor interest and support the company's growth prospects.
References:
[1] https://www.biospace.com/press-releases/celcuity-announces-issuance-of-new-patent-for-gedatolisib-that-extends-patent-exclusivity-into-2042
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet